- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Kidney Stone.
Displaying page 1 of 2.
EudraCT Number: 2021-001519-10 | Sponsor Protocol Number: ALN-GO1-008 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Di... | |||||||||||||
Medical condition: Recurrent calcium oxalate kidney stone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001924-37 | Sponsor Protocol Number: HJU1 | Start Date*: 2013-11-05 | |||||||||||
Sponsor Name:Fredericia Hospital | |||||||||||||
Full Title: Relaxation of the ureter during ureterorenoscopy | |||||||||||||
Medical condition: Elevated pressure in the upper urinary tract during ureterorenoscopy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005972-34 | Sponsor Protocol Number: HJ1 | Start Date*: 2006-03-22 |
Sponsor Name:Fredericia Hospital | ||
Full Title: Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten | ||
Medical condition: kidney stone | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004475-13 | Sponsor Protocol Number: 13.031 | Start Date*: 2014-03-05 | |||||||||||
Sponsor Name:Fredericia Hospital | |||||||||||||
Full Title: Pharmacological relaxation of the ureter when using access sheaths during ureterorenoscopy | |||||||||||||
Medical condition: Resistance in the ureter when inserting a ureteral access sheath during ureterorenoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000921-29 | Sponsor Protocol Number: ALLN-177-302 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Allena Pharmaceuticals, Inc. | |||||||||||||
Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2) | |||||||||||||
Medical condition: Enteric Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019469-26 | Sponsor Protocol Number: pRGF/016/09 | Start Date*: 2010-07-29 |
Sponsor Name:University of Aberdeen [...] | ||
Full Title: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha b... | ||
Medical condition: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine) and an alpha bl... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003328-35 | Sponsor Protocol Number: CHD062-13 | Start Date*: 2014-03-13 | |||||||||||
Sponsor Name:Centre Hospitalier Départemental Vendée | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003962-24 | Sponsor Protocol Number: VEN1 | Start Date*: 2008-10-15 | |||||||||||
Sponsor Name:Fredericia hospital | |||||||||||||
Full Title: visceral pain originating from the upper urinary tract - a randomised controlled trial on the effect of morphine and oxycodone in patients undergoing percutaneus nephrolithotomy (PCNL) | |||||||||||||
Medical condition: kidney stone | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005756-32 | Sponsor Protocol Number: HJ2 | Start Date*: 2007-01-18 |
Sponsor Name:Fredericia Hospital | ||
Full Title: Pharmacological modulation of the intrarenal pressure during endourological procedures in the upper urinary tract | ||
Medical condition: Kidney stones Benignant conditions in the upper urinary tract | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000975-33 | Sponsor Protocol Number: RDCRN_RKSC_6412 | Start Date*: 2013-11-19 |
Sponsor Name:Landspitali - The National University Hospital of Iceland | ||
Full Title: Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1 | ||
Medical condition: Adenine phosphoribosyltransferase deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000344-67 | Sponsor Protocol Number: DCR-PHXC-104 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hype... | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 3 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003576-12 | Sponsor Protocol Number: OC5-OL-02 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:OxThera Intellectual Property AB | |||||||||||||
Full Title: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 | |||||||||||||
Medical condition: Primary Hyperoxaluria (PH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003099-10 | Sponsor Protocol Number: DCR-PHXC-301 | Start Date*: 2019-06-12 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals Inc | |||||||||||||
Full Title: An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria | |||||||||||||
Medical condition: Primary Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Ongoing) ES (Ongoing) PL (Completed) IT (Ongoing) RO (Completed) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001346-17 | Sponsor Protocol Number: ALN-GO1-005 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Ongoing) Outside EU/EEA IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000684-33 | Sponsor Protocol Number: OC5-DB-02 | Start Date*: 2017-06-06 | |||||||||||
Sponsor Name:OxThera Intellectual Property AB | |||||||||||||
Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria | |||||||||||||
Medical condition: Primary Hyperoxaluria (PH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004352-33 | Sponsor Protocol Number: ALLN-177-301 | Start Date*: 2018-07-18 |
Sponsor Name:Allena Pharmaceuticals, Inc. | ||
Full Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study | ||
Medical condition: Enteric Hyperoxaluria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003098-91 | Sponsor Protocol Number: DCR-PHXC-201 | Start Date*: 2019-03-05 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyper... | |||||||||||||
Medical condition: Primary Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) PL (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003547-38 | Sponsor Protocol Number: ALLN-177-206 | Start Date*: 2018-07-17 |
Sponsor Name:Allena Pharmaceuticals, Inc. | ||
Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia | ||
Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001191-30 | Sponsor Protocol Number: RDEA594-401 | Start Date*: 2017-09-27 | |||||||||||
Sponsor Name:Ironwood Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared W... | |||||||||||||
Medical condition: Gout and moderate renal impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001552-19 | Sponsor Protocol Number: TOPMATEPY4067 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ... | |||||||||||||
Medical condition: New-onset or recent-onset epilepsy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.